SCHEMBL1325534

SCHEMBL1325534

c1ccc2c(c1)[nH]c1c(OCC3CO3)cccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
GLA P06280 1/20 0.53
DHFR P00374 1/20 0.50
KIF11 P52732 5/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP3A4 P08684 2/20 0.44
TSHR P16473 2/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HIF1A Q16665 1/20 0.44
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301228 1.00 ALDH1A1 (0.53) ALDH1A1GLADHFRKIF11TDP1
SCHEMBL619267 0.83 ALDH1A1 (0.53) ALDH1A1GLADHFRTDP1CYP3A4
SCHEMBL1351843 0.83 ALDH1A1 (0.53) ALDH1A1GLADHFRTDP1CYP3A4
SCHEMBL2997257 0.83 ALDH1A1 (0.53) ALDH1A1GLADHFRTDP1CYP3A4
SCHEMBL29363243 0.83 ALDH1A1 (0.53) ALDH1A1GLADHFRTDP1CYP3A4
SCHEMBL3979543 0.82 ALDH1A1 (0.51) ALDH1A1GLADHFRTDP1CYP3A4
SCHEMBL28097894 0.80 ALDH1A1 (0.49) ALDH1A1GLADHFRKIF11TDP1
SCHEMBL25385740 0.80 ALDH1A1 (0.49) ALDH1A1GLADHFRTDP1CYP3A4
SCHEMBL31475708 0.79 MEN1 (0.54) ALDH1A1GLADHFRKIF11TDP1
SCHEMBL729501 0.78 ALDH1A1 (0.65) ALDH1A1GLADHFRTDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756057-B1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LTD (IN) 2010-08-04 EP claimed
US-7705163-B2 Process for the preparation of carvedilol CIPLA LIMITED (IN) 2010-04-27 US claimed
US-20080234492-A1 Process for the Preparation of Carvedilol CIPLA LIMITED (IN) 2008-09-25 US claimed
EP-1756057-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL Cipla Ltd. (IN) 2007-02-28 EP claimed
WO-2005113502-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LIMITED (IN) 2005-12-01 WO claimed
CN-116042299-A Antiwear lubricating oil and preparation method thereof 徐武警 2023-05-02 CN disclosed
US-8058453-B2 Process for the preparation of Carvedilol Form II MATRIX LABORATORIES LTD. (IN) 2011-11-15 US disclosed
EP-1756057-B1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LTD (IN) 2010-08-04 EP disclosed
US-7705163-B2 Process for the preparation of carvedilol CIPLA LIMITED (IN) 2010-04-27 US disclosed
US-7705163-B2 Process for the preparation of carvedilol CIPLA LIMITED (IN) 2010-04-27 US disclosed
US-20090286991-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL FORM II TIANISH LABORATORIES PRIVATE LIMITED (IN) 2009-11-19 US disclosed
WO-2009115902-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL VIA SILYL PROTECTION OF SUBSTITUTED AMINE CADILA PHARMACEUTICALS LTD. (IN) 2009-09-24 WO disclosed
EP-1756057-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL Cipla Ltd. (IN) 2007-02-28 EP disclosed
EP-1756057-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL Cipla Ltd. (IN) 2007-02-28 EP disclosed
WO-2006060122-A9 CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE ARTESIAN THERAPEUTICS INC (US) 2006-08-17 WO disclosed
WO-2006060122-A2 CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE ARTESIAN THERAPEUTICS, INC. (US) 2006-06-08 WO disclosed
WO-2005113502-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LIMITED (IN) 2005-12-01 WO disclosed
WO-2005113502-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL CIPLA LIMITED (IN) 2005-12-01 WO disclosed
WO-2004113296-A1 A PROCESS FOR PREPARATION OF 1-[9H-CARBAZOL-4-YLOXY]- 3-[{2-(2-(-(METHOXY)PHENOXY)-ETHYL}-AMINO]-PROPAN-2-OL SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2004-12-29 WO disclosed
WO-1998009625-A1 SELECTIVE β3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234492-A1 Process for the Preparation of Carvedilol ADRB2, ADRB3, ADRB1 ALDH1A1 421/4885GLA 2151/4885DHFR 2735/4885
US-20090286991-A1 PROCESS FOR THE PREPARATION OF CARVEDILOL FORM II ADRB2, ADRA2C, ADRB1 ALDH1A1 931/4885GLA 1292/4885DHFR 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.